natgillin/translations-raw huggingface dataset:
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate.
4 mg zoledroonhapet vähendas oluliselt patsientide osakaalu, kellel tekkis vähemalt üks LST, pikendas aega esimese LST tekkimiseni keskmiselt >5 kuu võrra ning vähendas tüsistuste arvu patsiendi kohta aastas – luustiku haigestumuse taset.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of zoledronic acid 4 mg on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
4 mg zoledroonhappe toime hindamiseks luustikuga seotud tüsistuste (LST) suhte määrale, mille arvutamiseks LST (välja arvatud hüperkaltseemia ja täpsustatud varasem luumurd) koguarv jagati riskiperioodiga, uuriti topeltpimedas, randomiseeritud platseebokontrolliga uuringus 228 patsienti, kelle rinnavähi metastaaside esinemine luukoes oli dokumenteeritud.
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion
Zoledronic acid Accord 4 mg/5 ml infusioonilahuse kontsentraat
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronic acid Accord 4 mg/5 ml infusioonilahuse kontsentraat Zoledroonhape
Zoledronic Acid Accord can also be used to treat the hypercalcaemia caused by tumours.
Ravimit Zoledronic Acid Accord tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
Zoledronic Acid Accord can only be obtained with a prescription and must only be prescribed and given by a healthcare professional who has experience in the use of this type of medicine given into a vein.
Zoledronic Acid Accord on retseptiravim ja seda tohib välja kirjutada ja manustada üksnes tervishoiuspetsialist, kellel on kogemused selliste veeni manustatavate ravimite kasutamises.
Zoledronic Acid Accord concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Accordi kontsentraati ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic Acid Accord contains sodium.
Zoledronic acid Accord sisaldab naatriumi
Zoledronic Acid Accord is a medicine that contains the active substance zoledronic acid.
Zoledronic Acid Accord on ravim, mis sisaldab toimeainena soledroonhapet.
Zoledronic Acid Accord is a ‘generic medicine’.
Zoledronic Acid Accord on geneeriline ravim.
Zoledronic Acid Accord is given as a drip (infusion) into a vein which should take at least
Zoledronic acid Accordi manustatakse veeninfusiooni teel, mis peab kestma vähemalt
Zoledronic Acid Accord is not recommended for use in adolescents and children below the age of 18 years.
Zoledronic acid Accordi ei ole soovitatav kasutada alla 18-aastastel lastel ja noorukitel.
Zoledronic Acid Accord is supplied as a liquid concentrate in a vial.
Zoledronic acid Accordi turustatakse viaalides, milles on pulber.
Zoledronic Acid Accord must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronic acid Accordi võivad manustada ainult bisfosfonaatide intravenoosse, s.t veeni kaudu, manustamise koolituse läbinud tervishoiutöötajad.
Zoledronic Acid Accord must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronic acid Accordi võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is supplied as packs containing 1, 4 or 10 vials.
Zoledronic acid Actavis’e pakend sisaldab 1, 4 või 10 viaali.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion zoledronic acid
Zoledronic acid Actavis 4 mg/5 ml infusioonilahuse kontsenrtaat zoledroonhape
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion zoledronic acid
Zoledronic acid Actavis 4 mg/5 ml infusioonilahuse kontsentraat Acidum zoledronicum
Zoledronic acid Actavis can be given to people aged 65 years and over.
Zoledronic acid Actavis’t võivad kasutada ka 65-aastased ja vanemad patsiendid.
Zoledronic acid Actavis is a ‘generic medicine’.
Zoledronic acid Actavis on geneeriline ravim.
Zoledronic acid Actavis is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zoledronic acid Actavis’t ei soovitata kasutada raske neerupuudulikkusega patsientidel, kellel kreatiniinikliirens on <30 ml/min. zoledroonhappe kliinilistest uuringutest arvati välja patsiendid, kellel seerumi kreatiniinisisaldus oli
Zoledronic acid Actavis is not recommended for use in adolescents and children below the age of 18 years.
Zoledronic acid Actavis’t ei ole soovitatav kasutada alla 18-aastastel lastel ja noorukitel.
Zoledronic acid Actavis is supplied as a clear and colourless concentrate for solution for infusion (sterile concentrate) in a plastic vial.
Zoledronic acid Actavis’t turustatakse läbipaistva värvitu infusioonilahuse kontsentraadina (steriilse kontsentraadina) plastikviaalides.
Zoledronic acid Actavis is supplied as packs containing 1, 4 or 10 vials.
Zoledronic acid Actavis’t turustatakse pakendites, milles on kas 1, 4 või 10.
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Actavis’e lahust ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic acid Actavis must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronic acid Actavis’t võivad manustada ainult bisfosfonaatide intravenoosse, s.t veeni kaudu, manustamise koolituse läbinud tervishoiutöötajad.
Zoledronic acid Actavis must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronic acid Actavis’t võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid Actavis should not be used during pregnancy.
Zoledronic acid Actavis’t ei tohi kasutada raseduse ajal.
Zoledronic acid Actavis treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Raske neerupuudulikkusega TIH patsientidel võib ravi Zoledronic acid Actavis’ega alustada vaid pärast võimaliku riski/eeldatava kasu suhte hindamist.
Zoledronic acid Actavis treatment should be resumed at the same dose as that given prior to treatment interruption.
Ravi Zoledronic acid Actavis’ega tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic acid Actavis zoledronic acid
Zoledronic acid Actavis soledroonhape
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3 % of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
In vitro ei inhibeeri zoledroonhape inimese P450 ensüüme, ei biotransformeeru ning loomkatsetes eritub sapiga vaid < 3% manustatud annusest, mis viitab sellele, et maksal ei ole olulist osa zoledroonhappe farmakokineetikas.
Zoledronic acid has been associated with reports of renal dysfunction.
Zoledroonhape võib halvendada neerufunktsiooni.
Zoledronic acid has been associated with reports of renal dysfunction.
Zoledroonhappe kasutamisel on teatatud neerufunktsiooni häiretest.
Zoledronic Acid Hospira (5 mg in 100 ml ready-to-infuse solution) is administered via an infusion line and given at a constant infusion rate.
Zoledronic Acid Hospira’t (5 mg 100 ml-s manustamisvalmis infusioonilahuses) manustatakse püsiva infusioonikiirusega ühe infusioonisüsteemi kaudu.
Zoledronic Acid Hospira 4 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronic Acid Hospira 4 mg/100 ml infusioonilahus Zoledroonhape
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Normaalse neerufunktsiooniga patsientide puhul tohib Zoledronic Acid Hospira 4 mg/100 ml infusioonilahust kasutada kohe, ilma täiendava ettevalmistuseta.
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronic Acid Hospira 4 mg/100 ml infusioonilahus sisaldab 4 mg zoledroonhapet 100 ml-s infusioonilahuses koheseks kasutamiseks normaalse neerufunktsiooniga patsientidel.
Zoledronic Acid Hospira 4 mg/5 ml Sterile concentrate IV
Zoledronic Acid Hospira 4 mg/5 ml steriilne kontsentraat i.v.
Zoledronic Acid Hospira 5 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronic Acid Hospira 5 mg/100 ml infusioonilahus Zoledroonhape
Zoledronic Acid Hospira 5 mg/100 ml solution is used to treat Paget’s disease of the bone in adults.
Ravimi Zoledronic Acid Hospira 5 mg/100 ml lahust kasutatakse ka luu Pageti tõve raviks täiskasvanutel.
Zoledronic Acid Hospira can be given to people aged 65 years and over.
Zoledronic Acid Hospira’t võivad kasutada ka 65-aastased ja vanemad patsiendid.
Zoledronic Acid Hospira contains the active substance zoledronic acid.
Zoledronic Acid Hospira toimeaine on zoledroonhape.
Zoledronic Acid Hospira for infusion can be given to people aged 65 years and over.
Zoledronic Acid Hospira’t võivad kasutada ka 65-aastased ja vanemad patsiendid.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zoledronic Acid Hospira’l ei ole või on ebaoluline toime autojuhtimise ja masinate käsitsemise võimele.
Zoledronic Acid Hospira is a clear and colourless solution.
Zoledronic Acid Hospira on selge ja värvitu lahus.
Zoledronic Acid Hospira is a ‘generic’ and a ‘hybrid’ medicine.
Zoledronic Acid Hospira on geneeriline ja hübriidravim.
Zoledronic Acid Hospira is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic Acid Hospira manustatakse tilgutiga veeni (infusioon), see peab kestma vähemalt 15 minutit ja ravim tuleb manustada ainsa intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
Zoledronic Acid Hospira is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic Acid Hospira’t manustatakse tilgutiga veeni (infusioon), see peab kestma vähemalt 15 minutit ja ravim tuleb manustada ainsa intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
Zoledronic Acid Hospira is not recommended for anyone under 18 years of age.
Zoledronic Acid Hospira’t ei soovitata alla 18-aastastele isikutele.
Zoledronic Acid Hospira is not recommended for use in adolescents and children below the age of 18 years.
Zoledronic Acid Hospira’t ei ole soovitatav kasutada alla 18-aastastel lastel ja noorukitel.
Zoledronic Acid Hospira is ready for use.
Zoledronic Acid Hospira on valmis kasutamiseks.
Zoledronic Acid Hospira may also cause other side effects
Zoledronic Acid Hospira võib põhjustada ka teisi kõrvaltoimeid
Zoledronic Acid Hospira must not be mixed or given intravenously with any other medicinal product and must be given through a separate infusion line at a constant infusion rate.
Zoledronic Acid Hospira’t ei tohi segada või manustada intravenoosselt koos mistahes teise ravimiga ning seda tuleb manustada püsiva infusioonikiirusega eraldi infusioonisüsteemi kaudu.
Zoledronic Acid Hospira must not be mixed or given intravenously with any other medicinal products.
Zoledronic Acid Hospira’t ei tohi segada ühegi teise ravimiga ega intravenoosselt manustada.
Zoledronic Acid Hospira must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic Acid Hospira’t ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
Zoledronic Acid Hospira must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic Acid Hospira’t ei tohi segada teiste infusioonilahustega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as ‘IV’ administration).
Zoledronic Acid Hospira’t tohivad manustada ainult bisfosfonaatide intravenoosse, st veeni kaudu manustamise (seda nimetatakse ka i.v. manustamiseks) koolituse läbinud tervishoiutöötajad.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronic Acid Hospira’t tohivad manustada ainult bisfosfonaatide intravenoosse, st veeni kaudu manustamise (seda nimetatakse ka i.v. manustamiseks) koolituse läbinud tervishoiutöötajad.
Zoledronic Acid Hospira should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronic Acid Hospira’t tuleb manustada ühe intravenoosse infusioonina, mille kestus on vähemalt 15 minutit.
Zoledronic Acid Hospira treatment should be resumed at the same dose as that given prior to treatment interruption.
Ravi Zoledronic Acid Hospira’ga tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic Acid Hospira with food and drink
Zoledronic Acid Hospira koos toidu ja joogiga
Zoledronic Acid Hospira, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronic Acid Hospira’t, mis lahjendatakse edasi 100 ml-s (vt lõik 6.6), tuleb manustada ühe intravenoosse infusioonina, mille kestus on vähemalt 15 minutit.
Zoledronic acid is contraindicated in breast-feeding women (see section 4.3).
Zoledroonhape on vastunäidustatud rinnaga toitmise ajal (vtlõik 4.3).
Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zoledroonhape’t ei soovitata kasutada raske neerupuudulikkusega patsientidel, kellel kreatiniinikliirens on < 30 ml/min.
Zoledronic acid medac 4 mg/100 ml solution for infusion
Zoledroonhape medac 4 mg/100 ml infusioonilahus
Zoledronic acid medac 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zoledroonhape medac 4 mg/100 ml infusioonilahust võib normaalse neerufunktsiooniga patsientidele manustada otse, ilma täiendava ettevalmistuseta.
Zoledronic acid medac 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledroonhape medac 4 mg/100 ml infusioonilahus sisaldab 4 mg zoledroonhapet 100 ml infusioonilahuses, mida võib normaalse neerufunktsiooniga patsientidele koheselt manustada.
Zoledronic acid medac 4 mg/100 ml solution for infusion should be given as a single intravenous infusion in no less than 15 minutes.
Zoledroonhape medac’i 4 mg/100 ml infusioonilahus tuleb manustada ühe intravenoosse infusioonina vähemalt 15 minuti kestel.
Zoledronic acid medac 4 mg/100 ml solution for infusion Zoledronic acid
Zoledroonhape medac 4 mg/100 ml infusioonilahus Acidum zoledronicum
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Zoledroonhape medac 4 mg/5 ml infusioonilahuse kontsentraat
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledroonhape medac 4 mg/5 ml infusioonilahuse kontsentraat Acidum zoledronicum
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledroonhape medac’i 4 mg/5 ml infusioonilahuse kontsentraat, mis lahjendatakse hiljem 100 ml-s (vt lõik 6.6), tuleb manustada ühe intravenoosse infusioonina vähemalt 15 minuti kestel.
Zoledronic acid medac 4mg/100ml solution for infusion
Zoledroonhape medac 4 mg / 100 ml infusioonilahus
Zoledronic acid medac 4mg/5ml concentrate for solution for infusion
Zoledroonhape medac 4 mg / 5 ml infusioonilahuse kontsentraat
Zoledronic acid medac can be given to people aged 65 years and over.
Zoledroonhape medac’it võivad kasutada ka 65-aastased ja vanemad patsiendid.
Zoledronic acid medac contains sodium
Zoledroonhape medac sisaldab naatriumi
Zoledronic acid medac is given as a drip (infusion) into a vein which should take at least
Zoledroonhape medac’it manustatakse veeninfusiooni teel, mis peab kestma vähemalt
Zoledronic acid medac is not recommended for use in adolescents and children below the age of 18 years.
Zoledroonhape medac’it ei soovitata kasutada lastel ja noorukitel vanuses kuni 18 aastat.
Zoledronic acid medac is supplied as a concentrate for solution for infusion in a 5 ml plastic vial made of clear, colourless plastic (cycloolefine copolymer) with rubber stopper (type I bromobutyl) and sealed with flip-off seal (aluminium and polypropylene).
Zoledroonhape medac’it turustatakse infusioonilahuse kontsentraadina 5 ml plastviaalis, mis on valmistatud läbipaistvast värvitust tsükloolefiini kopolümeerist, kummikorgiga (I tüüpi bromobutüül) ja (alumiiniumist ja polüpropüleenist) äratõmmatava sulguriga.
Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Zoledroonhape medac’it turustatakse pakendis, mis sisaldab 1 pudelit, või 4 või 10 pakendiga mitmikpakendites, millest igas on 1 pudel.
Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Zoledroonhape medac’it turustatakse ühte pudelit sisaldava pakendina või mitmikpakenditena, mis koosnevad 4 või 10 pakendist, igaühes üks pudel.
Zoledronic acid medac is supplied as solution for infusion in a 100 ml colourless glass bottle (type I) with rubber stoppers (halobutyl, fluoropolymer coated) and aluminium flip-off caps.
Zoledroonhape medac’it turustatakse infusioonilahusena 100 ml värvitus (I tüüpi) klaaspudelis, millel on kummikorgid (halobutüül, kaetud fluoropolümeeriga) ja alumiiniumist äratõmmatavad sulgurid.
Zoledronic acid medac must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledroonhape medac’i infusioonilahust ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega, ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic acid medac must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledroonhape medac’it võivad manustada ainult bisfosfonaatide intravenoosse, s.t veeni kaudu, manustamise koolituse läbinud tervishoiutöötajad.
Zoledronic acid medac must only be prescribed and administered to patients by health care professionals experienced in the administration of intravenous bisphosphonates.
Zoledroonhape medac’it võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid medac must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledroonhape medac’it võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid medac treatment should be resumed at the same dose as that given prior to treatment interruption.
Ravi Zoledroonhape medac’iga tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronic acid Teva’t võivad manustada ainult bisfosfonaatide intravenoosse, s.t veeni kaudu, manustamise koolituse läbinud tervishoiutöötajad.
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion
Zoledronic acid Mylan 4 mg/5 ml infusioonilahuse kontsentraat
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronic acid Mylan 4 mg/5 ml infusioonilahuse kontsentraat Acidum zoledronicum
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronic acid Mylan 4 mg/5 ml infusioonilahuse kontsentraat Zoledroonhape
Zoledronic acid Mylan 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronic acid Mylan’i 4 mg/5 ml infusioonilahuse kontsentraat, mis lahjendatakse hiljem 100 ml-s (vt lõik 6.6), tuleb manustada ühe intravenoosse infusioonina vähemalt 15 minuti kestel.
Zoledronic acid Mylan can be given to people aged 65 years and over.
Zoledronic acid Mylan’i võivad kasutada ka 65 - aastased ja vanemad patsiendid.
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Mylan’i kontsentraati ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega, ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic acid Mylan concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Mylan’i kontsentraati ei või segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega, ja peab manustama üksiku intravenoosse lahusena eraldi infusioonivooliku kaudu.
Zoledronic acid Mylan is a clear and colourless concentrate for solution for infusion.
Zoledronic acid Mylan on läbipaistev ja värvitu infusioonikontsentraat.
Zoledronic acid Mylan is a ‘generic medicine’.
Zoledronic acid Mylan on geneeriline ravim.
Zoledronic acid Mylan is given as a drip (infusion) into a vein which should take at least
Zoledronic acid Mylan manustatakse veeninfusiooni teel, mis peab kestma vähemalt
Zoledronic acid Mylan is not recommended for use in adolescents and children below the age of 18 years.
Zoledronic acid Mylan’i ei ole soovitatav kasutada alla 18 - aastastel lastel ja noorukitel.
Zoledronic acid Mylan is supplied as packs containing 1, 4 or 10 vials or as multipacks comprising 4 packs, each containing 1 vial.
Zoledronic acid Mylan turustatakse pakendites, mis sisaldavad 1, 4 või 10 viaali või rühmapakendis, mis sisaldab 4 pakendit, igas 1 viaal.